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Abstract 
Background: Pentavalent antimonials are still the first choice treatment for 
leishmaniasis, but with low efficacy and resistance is emerging. In the present study, 
the effect of meglumine antimoniate (MA, Glucantime) combined with paromomy-
cin, miltefosine or allopurinol on in vitro susceptibility of Leishmania tropica resistant 
isolate was evaluated. 
Method: The drugs were obtained from commercial sources and diluents of each 
drug in medium were prepared on the day of experiment. J774 A.1 murine macro-
phage cell lines were attached to the cultured on slide and incubated at 37 0C with 
5% CO2 for 24 h. Then the stationary phase promastigotes were added to the cells 
and after 4 hrs of incubation different concentrations of MA, paromomycin, 
miltefosine or allopurinol were added and incubated for an additional of 72 h. Then 
the slides were dried and fixed with methanol, stained by Giemsa and studied under 
a light microscope. Drug activity was evaluated by assessing the macrophage infec-
tion rate and the number of amastigotes per infected macrophage was done by ex-
amining 100 macrophages. The experiment was done in triplicates. 
Result: Various concentrations of MA along with paromomycin, miltefosine or 
allopurinol significantly inhibited (P<0.01) the proliferation of L. tropica amastigote 
stage in the macrophage cell line as compared with MA alone or positive control. 
Conclusion: Combination of Glucantime with paromomycin, miltefosine or allo-
purinol showed a synergistic effect on the clinical isolate of L. tropica in vitro. Use of 
combination therapy is a new hope and a logical basis for therapy of the patients 
with cutaneous leishmaniasis. Further investigations are needed to evaluate the 
therapeutic effects of these drugs on the CL patients. 
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Introduction 
 
eishmaniasis (CL) is caused by 
Leishmania spp and transmitted by 
various species of sandfly (1). CL is 
still a significant public health problem in en-
demic areas particularly in Iran (2). It is a ma-
jor health problem in endemic areas of Iran 
(3). Leishmanaisis treatment and control are 
difficult because of the variety of epidemiolog-
ical and clinical forms, different species of an-
imal reservoirs and biological diference insand 
fly vectors (4). Available treatments are associ-
ated with adverse effects and are fairly effec-
tive (4). Although vaccination seems to be the 
most feasible and cost effective method for 
control of the disease currently there is no 
vaccine available (5). 
  At present, treatment of leishmaniasis in 
endemic areas is mainly restricted to chemo-
therapy (6). The first-line drug for CL in Iran 
is meglumine antimoniate (MA, Glucantime) 
but the efficacy is often questioned and re-
sistance is emerging (7). Emphasis is presently 
focused on application of combination thera-
py strategies. Therefore, there is an urgent 
need for more effective with less duration 
therapeutic regimens and development of new 
treatment protocols. Combination therapy 
with MA and the second-line drugs including 
paromomycin, miltefosine or allopurinol is the 
only hope.  
This study was aimed to evaluate various 
concentrations of meglumine antimoniate in 
combination with either paromomycin, 
miltefosine or allopurinol compared with each 
drug alone or positive control on in vitro sus-
ceptibility of L. tropica resistant isolate using an 
amastigote-macrophage model. 
 
Materials and Methods 
 
Parasite and macrophage culture 
Macrophage cell line J774A.1 (ECACC 
number 91051511) was purchased from Pas-
ture Institute,Tehran, Iran. Macrophages were 
kept in the laboratory by cryopreservation in 
liquid nitrogen and then by successive subcul-
tures in RPMI- 1640 medium, supplemented 
with 15% heat-inactivated fetal calf serum 
(FCS), 1% penicillin and streptomycin 
(200µg/ml).Viability test using macrophage 
cell line and clinical stage of parasite 
(amastigotes) was performed by adding 90μl 
of trypan blue solution (0.2%) in saline solu-
tion containing 0.01% sodium aside to 10μl of 
cell suspension (106 cells/ml). After 2 minutes, 
the cells were counted under a light micro-
scope and viability was assessed as follows: 
Viability= live cells / all counted cells × 100 
Resistant isolate to meglumine antimoniate 
was recovered from a CL patient in Bam, sou-
theastern Kerman province of Iran. This resis-
tant isolate was detected by nested-PCR as L. 
tropica and further identified by conventional 
PCR for MDR1 gene (8). Subsequently the 
DNA extract was sequenced and recorded in 
Gene Bank under HM854717 Accession 
Number. 
 
Drugs  
Meglumine antimoniate (MA), paromomycin, 
miltefosine and allopurinol were obtained 
from commercial sources. All drugs dilutions 
were prepared in RPMI- 1640 medium fresh 
on the day of assay. Various concentrations of 
MA, paromomycin, miltefosine or allopurinol 
alone or MA in combination with either paro-
momycin, miltofosine or allopurinol as com-
pared with positive control were prepared. In 
the first combination, the concentration of 
MA remained constant while other drugs were 
used in decreasing order of concentrations. 
While, in the second combination, the concen-
trations of other drugs were constant and MA 
was used in a decreasing order of concentra-
tions. For each amastigote assay 200μl of J774 
A.1 murine macrophage cell lines (106 
cells/ml) were attached to the 8-chamber 
slide(Lab- Tek, Nalge Nunc International NY, 
L 
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USA), and incubated at 37 0C,with 5% CO2 for 
24 hrs. Then the promastigotes in stationary 
phase were added to the macrophages and 
incubated for 24 hrs at different concentration 
of MA in combination with paromomycin, 
miltefosine or allopurinol and incubated for 
additional 72 h. Then the slides were dried, 
fixed with methanol, stained by Giemsa and 
studied under a light microscope. Drug activ-
ity was evaluated by two criteria; first, the 
mean infection rate of 100 macrophages and 
the second, the number of amastigotes in the 
macrophages by examining 100 macrophages. 
Every experiment was repeated three times. 
 
Results 
 
 The effect of MA, paromomycin, 
miltefosine or allopurinol alone on in vitro sus-
ceptibility of L. tropica resistant isolate (Table 
1) showed that various concentrations of the 
drugs inhibited the growth of amastigotes in 
each macrophage as compared to the control 
group (P<0.01). However, the most effect was 
observed at concentration of 100µg/ml for 
each drug. In the second step, the effect of a 
constant concentration of MA coupled with 
either paromomycin, miltefosine or allopuri-
nol was assessed on the same resistant isolate 
(Table 2). The finding indicated that different 
concentration of combined drugs inhibited 
more significantly than each drug alone the 
mean number of infected macrophages and 
the mean number of amastigotes per each 
macrophage in comparison to the control 
group (P<0.01). 
In the last series, variable concentrations of 
MA were coupled with each drug alone (Table 
3). Again a significant effect (P<0.01) was ob-
served similar to the constant concentrations 
of MA, when the infected macrophages and 
the mean number of amastigotes were eva-
luated.  
 
 
Table 1: Comparative evaluation of the effect of meglumine antimoniate (MA), paromomycin (Paro), miltefo-
sine (Milt) or allopurinol (Allo) alone on in vitro susceptibility of Leishmania tropica resistant isolate 
 
 
Drugs  MA 
(µg/µl) 
Paro 
(µg/µl) 
Milt 
(µg/µl) 
Allo 
(µg/µl) 
 
 
Concentration 
No. of in-
fected 
macrophage 
±SD 
No. of 
amastigote 
±SD 
No. of in-
fected 
macrophage 
±SD 
No. of 
amastigote 
±SD 
No. of in-
fected 
macrophage 
±SD 
No. of 
amasti-
gote 
±SD 
No. of 
infected 
macro-
phage 
±SD 
No. of 
amastigote 
±SD 
          
0.00(Control) 65.33±2.58 104.67±5.58 65.33±2.517 104.67±5.508 65.33±2.58 104.67±5.5
1 
65.33±2.52 104.67±5.51 
6.25 64.00±2.00 96.00±5.29 62.33±2.082 101.33±3.215 77.67±6.66 114.33±8.1 64.00±2.00 96.00±5.29 
12.50 57.67±3.51 76.00±4.58 57.33±2.082 94.67±10.066 65.33±2.52 85.00±5.51 57.67±3.51 76.00±4.58 
25.00 51.33±4.04 77.67±0.10 54.33±2.082 61.67±2.082 48.67±0.58 94.67±5.52 51.33±4.04 77.67±0.10 
50.00 46.00±1.00 64.67±4.16 44.67±3.055 58.00±3.606 40.33±2.52 54.67±4.16 46.00±1.00 64.67±4.16 
100.00 8.67±2.08 10.33±2.31 20.33±2.517 23.67±3.055 10.33±1.53 12.67±1.53 8.67±2.08 10.33±2.31 
  
A significant difference between various concentrations of MA, Paro, Milt or Allo and positive control was 
observed (P< 0.01). 
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Table 2: Comparative evaluation of the effect of meglumine antimoniate(MA, 100 or 50 µg/ml) combined 
with various concentrations of paromomycin (Paro), miltefosine (Milt) or allopurinol (Allo) on in vitro suscep-
tibility of Leishmania tropica resistant isolate 
 
Drugs  MA+ Paro+Medium 
(µg/µl) 
MA+ Milt+Medium 
(µg/µl) 
MA+ Allo+Medium 
(µg/µl) 
 
 
Concentration  
No of in-
fected 
macrophage 
±SD 
No of 
amastigote 
±SD 
No of infected 
macrophage 
±SD 
No of amas-
tigote 
±SD 
No of infected 
macrophage 
±SD 
No of amas-
tigote 
±SD 
0.00(Control) 65.33±2.52 104.67±5.51 65.33±2.52 104.67±5.51 65.33±2.52 104.67±5.51 
100+100 2.33±0.58 2.33±0.58 1.00±1.00 1.00±1.00 9.33±1.53 9.67±1.53 
50+50+100 7.00±1.00 7.76±1.16 6.00±1.00 7.00±1.00 16.00±4.36 23.33±7.64 
50+25+125 39.00±1.00 54.00±3.61 40.33±1.53 54.33±2.89 26.67±4.16 37.00±6.56 
50+12.5+137.5 41.68±3.51 58.00±3.65 41.33±2.52 57.00±3.61 36.67±4.16 53.00±7.00 
50+6.25+143.75 43.00±3.61 64.33±4.04 46.00±1.00 61.33±2.31 44.33±3.51 73.00±6.25 
A significant difference between MA combined with various concentrations of Paro, Milt or Allo and positive 
control was observed (P< 0.01). 
 
Table 3: Comparative evaluation of the effect of paromomycin (100 or 50 µg/ml), miltefosine (100 or 50 
µg/ml) or allopurinol (100 or 50 µg/ml) combined with various concentrations of meglumine antimoniate 
(MA) on in vitro susceptibility of Leishmania tropica resistant isolate 
 
Drugs Paro+MA +Medium 
(µg/µl) 
Milt+MA +Medium 
(µg/µl) 
Allo+MA +Medium 
(µg/µl) 
 
 
Concentration  
No. of in-
fected 
macrophage 
±SD 
No. of amas-
tigote 
±SD 
No. of infected 
macrophage 
±SD 
No. of amas-
tigote 
±SD 
No of infected 
macrophage 
±SD 
No. of amas-
tigote 
±SD 
0.00(Control) 65.33±2.52 104.67±5.51 65.33±2.517 104.67±5.508 65.33±2.52 104.67±5.51 
100+100 1.00±1.00 1.00±1.00 0.67±1.555 0.67±1.555 6.00±1.00 6.33±1.53 
50+50+100 7.67±1.53 11.00±1.00 9.00±2.000 10.33±2.517 14.00±4.00 21.33±5.86 
50+25+125 33.00±2.00 46.67±3.79 42.33±1.528 63.00±2.646 28.00±4.16 49.33±6.56 
50+12.5+137.5 37.33±1.53 55.00±3.61 50.00±2.646 83.00±4.000 36.00±2.65 58.33±1.16 
50+6.25+143.75 46.33±2.52 83.00±5.13 57.33±3.055 97.00±5.292 45.67±3.51 60.67±3.06 
A significant difference between Paro, Milt or Allo combined with various concentrations of MA and positive 
control was observed (P< 0.01) 
 
Discussion  
 
Leishmaniasis continues to be an important 
public health challenge in endemic countries 
(4). The treatment of choice for this disease 
has long been pentavalet antimony com-
pounds such as meglumine antimoniate 
(Glucantime) and sodium stibogluconate 
(Pentostam). These drugs are no longer effec-
tive in most tropical and sub-tropical countries 
where the two anthroponotic leishmaniasis 
(ACL and AVL) due to L. tropica and L. dono-
vani are present (8, 9). Resistance to these 
drugs have emerged in many foci and widely 
spread throughout the endemic areas (6). The 
main problem to the success of combination 
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treatment in preventing the emergence of re-
sistance will be inadequate treatment including 
incorrect dosing, sub-standard drugs, poor 
adherence and unusual pharmacokinetics (10).  
Combination treatments were highly effec-
tive and really could make a major contribu-
tion to global leishmaniasis control at in vitro 
level (11). The theory underlying combination 
drug treatment for most infectious diseases 
such as HIV/AIDES, malaria, leprosy and 
tuberculosis is now well known, and the same 
general principle is now widely accepted for 
leishmaniasis. If two drugs are used with dif-
ferent modes of actions, then they could help-
fully prevent effectively emergence of the new 
resistant mutant (12). 
 Hopefully the application of pentavalent anti-
monials including meglumine antimoniate as the 
first-line of treatment along with a second-line 
drug such as paromomycin, miltefosine or allo-
purinol with different modes of action would 
synergistically reduce the number of Leishmania 
parasite, inhibiting the proliferation of the clini-
cal stage within each macrophage and eventually 
limits the burden of the disease (6). Although 
the effect of MA in combination with each drug 
was significantly reduced, the two indices related 
to the amastigote-macrophage model, however, 
the combination of MA along with par-
omomycin showed the highest effect, followed 
by MA plus miltefosine or MA coupled with 
allopurinol.  
 
Conclusion 
 
Since combination effect on the clinical 
stage in an amastigote- macrophage model, it 
could be a new hope and a logical basis for 
therapy of the patients with CL. Further stud-
ies are required to evaluate the therapeutic ef-
fects of these drugs on the CL patients in en-
demic countries.  
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